(Q30579320)

English

Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Le Corfec E

1

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Chevret S

2

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Costagliola D

3

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

language of work or name

0 references

publication date

1 July 1999

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Statistics in Medicine

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1803-17; discussion 1819

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

A controlled trial of zidovudine in primary human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Size and power of two-sample tests of repeated measures data

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Stratification of summary statistic tests according to missing data patterns

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Intent-to-treat analysis for longitudinal studies with drop-outs.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Intention-to-treat analyses for incomplete repeated measures data.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Testing for treatment differences with dropouts present in clinical trials--a composite approach

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Estimating rates of change in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Statistical handling of drop‐outs in longitudinal clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1803%3A%3AAID-SIM217%3E3.0.CO%3B2-Q

21 January 2018

Identifiers

10.1002/(SICI)1097-0258(19990730)18:14<1803::AID-SIM217>3.0.CO;2-Q

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

release_zw2yg7uxo5g5jg2dez3x5w5yze

1 reference

https://api.fatcat.wiki/v0/release/zw2yg7uxo5g5jg2dez3x5w5yze

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30579320&oldid=1987413704"